skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Commercial Availability of Alpha-Emitting Radionuclides for Medicine

Abstract

Alpha-emitting radionuclides provide effective cell-killing properties and have been shown to be effective in cancer treatment. The number of different alpha emitters having suitable physical and chemical characteristics for applications in medicine is relatively few. Development and testing of new radiopharmaceuticals requires a reliable supply of alpha-emitters in high quality, with timely delivery, but at reasonable cost. Applications and commercial availability of the follow alpha emitters are reviewed: Actinium-225, bismuth-213, astatine-211, radium-223, bismuth-212, radium-224, radium-226, terbium-149, and thorium-227. Recommendations for improving the supply of these alpha emitters include an increased federal commitment (through funding and joint-agency cooperation), establishing new production capabilities, and strengthening federal-private partnerships with companies involved in helping to meet critical radionuclide supplies.

Authors:
Publication Date:
Research Org.:
Pacific Northwest National Lab. (PNNL), Richland, WA (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
949917
Report Number(s):
PNNL-SA-59529
ST6001030; TRN: US0901919
DOE Contract Number:  
AC05-76RL01830
Resource Type:
Journal Article
Journal Name:
Current Radiopharmaceuticals, 1(3):127-134
Additional Journal Information:
Journal Volume: 1; Journal Issue: 3
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; ACTINIUM 225; ASTATINE 211; AVAILABILITY; BISMUTH 212; BISMUTH 213; CELL KILLING; MEDICINE; NEOPLASMS; PRODUCTION; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIUM 223; RADIUM 224; RADIUM 226; RECOMMENDATIONS; TERBIUM 149; TESTING; THORIUM 227; Alpha-Emitting, Radionuclides, cancer treatment, radiopharmaceuticals, Actinium-225, radium-223, bismuth-212, Alpha emitters

Citation Formats

Fisher, Darrell R. Commercial Availability of Alpha-Emitting Radionuclides for Medicine. United States: N. p., 2008. Web. doi:10.2174/1874471010801030127.
Fisher, Darrell R. Commercial Availability of Alpha-Emitting Radionuclides for Medicine. United States. https://doi.org/10.2174/1874471010801030127
Fisher, Darrell R. 2008. "Commercial Availability of Alpha-Emitting Radionuclides for Medicine". United States. https://doi.org/10.2174/1874471010801030127.
@article{osti_949917,
title = {Commercial Availability of Alpha-Emitting Radionuclides for Medicine},
author = {Fisher, Darrell R},
abstractNote = {Alpha-emitting radionuclides provide effective cell-killing properties and have been shown to be effective in cancer treatment. The number of different alpha emitters having suitable physical and chemical characteristics for applications in medicine is relatively few. Development and testing of new radiopharmaceuticals requires a reliable supply of alpha-emitters in high quality, with timely delivery, but at reasonable cost. Applications and commercial availability of the follow alpha emitters are reviewed: Actinium-225, bismuth-213, astatine-211, radium-223, bismuth-212, radium-224, radium-226, terbium-149, and thorium-227. Recommendations for improving the supply of these alpha emitters include an increased federal commitment (through funding and joint-agency cooperation), establishing new production capabilities, and strengthening federal-private partnerships with companies involved in helping to meet critical radionuclide supplies.},
doi = {10.2174/1874471010801030127},
url = {https://www.osti.gov/biblio/949917}, journal = {Current Radiopharmaceuticals, 1(3):127-134},
number = 3,
volume = 1,
place = {United States},
year = {Mon Sep 15 00:00:00 EDT 2008},
month = {Mon Sep 15 00:00:00 EDT 2008}
}